Guggenheim Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating restated by equities researchers at Guggenheim in a research report issued to clients and investors on Friday,Benzinga reports.

DYN has been the topic of a number of other research reports. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Friday, January 10th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Robert W. Baird started coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $49.91.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN traded down $0.17 on Friday, hitting $13.52. The company’s stock had a trading volume of 564,242 shares, compared to its average volume of 2,421,110. Dyne Therapeutics has a 12 month low of $13.49 and a 12 month high of $47.45. The stock’s 50-day moving average is $24.32 and its two-hundred day moving average is $32.77. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -3.79 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jason P. Rhodes sold 782 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the transaction, the director now directly owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. This trade represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,071 shares of company stock worth $606,476 over the last 90 days. Insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. State of New Jersey Common Pension Fund D bought a new stake in Dyne Therapeutics in the third quarter valued at about $1,588,000. Jennison Associates LLC grew its stake in shares of Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after purchasing an additional 19,730 shares during the period. RA Capital Management L.P. raised its holdings in shares of Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after buying an additional 331,940 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after buying an additional 84,760 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Dyne Therapeutics in the 2nd quarter valued at $4,447,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.